GLP-1 medications drive new demand for skin tightening treatments

The rapid rise of GLP-1 medications, such as Ozempic and Wegovy, is driving new trends in the cosmetic and dermatology sectors. As patients experience significant weight loss, many are seeking treatments for skin laxity and reduced facial volume, a phenomenon sometimes referred to as ‘Ozempic face’. Non-invasive ultrasound technologies, including Sofwave, are being utilized to address skin firmness and contouring.

In Australia, the use of these medicines has grown substantially. Research indicates that sales of GLP-1 medicines for type 2 diabetes increased nearly tenfold over five years. Estimates suggest hundreds of thousands of Australians access these medications monthly, with significant private use driven by weight management. Modeling by EY suggests adoption could reach between 17% and 30% of Australian adults within a decade.

On an individual level, public figures like Chrissy Metz have shared their experiences using GLP-1 medications to manage weight and improve mobility. Metz reported a 63-pound weight loss, noting that the medication helped alleviate joint pain and inflammation despite facing public criticism regarding her choice of treatment.